rybrevant lazcluze news - Search News

Combination extends survival vs. standard first-line therapy for advanced lung cancer

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung cancer, according to the agents’ manufacturer.The OS benefit with amivantamab-vmjw (Rybrevant,

CNBC on MSN · 2d

J&J says its lung cancer drug combination keeps people alive longer

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year longer than AstraZeneca's Tagrisso in a clinical trial. J&J is trying to supplant AstraZeneca's blockbuster Tagrisso,

J&J says cancer drug combination showed survival benefit over Tagrisso

Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung cancer live longer.

Becker's Hospital Review · 1d

Drug extends survival in lung cancer patients: J&J

Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung cancer that has specific epidermal growth factor receptor mutations.

Business Insider · 3d

Johnson & Johnson’s rybrevant plus lazcluze improve survival in lung cancer

Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from

Rybrevant Plus Lazcluze Improves Survival for EGFR+ NSCLC

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...

With key win over AstraZeneca's Tagrisso, J&J touts Rybrevant-Lazcluze combo as 'new standard of care'

Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...

J&J says Rybrevant combo has survival edge over Tagrisso

Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to ...

GlobalData on MSN2d

J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial

Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...

Can an epilepsy drug do more than reduce seizures?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

1d

InnovationRx: Medical Debts Will Be Erased From Credit Histories

In this edition of InnovationRx, medical debts will be erased from credit histories, this farm is doubling down on raw milk ...

1d

Genmab’s Strategic Positioning and Promising Clinical Data Drive Buy Rating with $50 Price Target

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Genmab (GMAB – Research Report). The associated price target ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results